Dermatology Times has turned its attention to the role of "biotics" in skincare — prebiotics, probiotics and postbiotics — a category that keeps growing on shelf space while the clinical evidence base grows more slowly.

The publication's coverage lands at a moment when patients are already asking about the ingredient labels. Fermented extracts, lysates and bacterial cultures now appear across cleansers, moisturizers and serums marketed for acne, eczema, rosacea and general barrier repair. What the piece signals is a push to sort marketing language from what a dermatologist can actually tell a patient.

What are the 'biotics, practically?

The terminology matters because the three categories do different things.

• Prebiotics are substrates that feed beneficial microbes already on the skin — think sugars and fibers formulated to shift the microbiome's balance.
• Probiotics are live microorganisms, which raises formulation and stability questions most skincare products sidestep.
• Postbiotics are the byproducts or lysates of those organisms — the metabolites and fragments that can be bottled more reliably than live bugs.

Most products on the market lean on postbiotic or fermented ingredients precisely because live cultures are hard to keep alive in a jar. That distinction is one practitioners can use at the bedside when a patient hands over a label.

What does this change for the clinic?

In practice, probably conversation management more than prescription habits. The skin microbiome is a legitimate and active research area — dysbiosis has been linked in the literature to atopic dermatitis, acne and rosacea — but microbiome-directed skincare sits closer to cosmeceutical territory than to drug therapy. Claims on packaging typically outpace the trial data behind them.

For dermatologists, the useful posture is the one the coverage encourages: engage with the category rather than dismiss it, because patients are buying these products regardless. Knowing whether a formula contains a live probiotic, a prebiotic feedstock or a postbiotic lysate lets a clinician give a grounded answer about plausible benefit versus hype.

Where the evidence conversation is heading

Interest in 'biotics tracks with the broader shift toward barrier-first dermatology — ceramides, microbiome support and gentle formulation as the backbone of maintenance therapy alongside actives. The open question the field keeps circling is standardization: which strains, which concentrations, and which endpoints define a meaningful effect. Without that, category claims stay soft.

Dermatology Times framing the topic for its physician audience suggests the discussion is moving from beauty counters into exam rooms, where the standard is different. Expect the practical takeaway for clinicians to keep refining as formulation science and trial design catch up to the marketing.